Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ionis Pharmaceuticals, Inc. - Common Stock
(NQ:
IONS
)
74.83
+0.05 (+0.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ionis Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Ionis Reveals Positive Results From Anti-Blood Clot Therapy In Hemodialysis
↗
July 28, 2022
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced positive topline results of the Phase 2b clinical trial of fesomersen in patients with end-stage renal disease (ESRD) on hemodialysis.
Via
Benzinga
Where Ionis Pharmaceuticals Stands With Analysts
↗
July 26, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings within the last quarter:
Via
Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
↗
July 26, 2022
The U.S. Food and Drug Administration (FDA) has accepted Biogen’s (NASDAQ: BIIB) New Drug Application (NDA) for its lead asset Tofersen for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis...
Via
Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
↗
July 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
↗
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Recap: Ionis Pharmaceuticals Q1 Earnings
↗
May 04, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Expert Ratings For Ionis Pharmaceuticals
↗
April 01, 2022
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Via
Benzinga
Recap of Wednesday's Biotech Catalysts - End of The Day Summary
↗
July 20, 2022
Via
Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
↗
July 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Best Biotech Stocks to Buy in July 2022
↗
July 08, 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.
Via
InvestorPlace
Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks
↗
March 17, 2022
Via
Benzinga
Cathie Wood's Ark Invest Sheds $35M In 3D Printing Company Stratasys — What It Bought Instead
↗
July 06, 2022
As the market reopened following the long July 4 weekend, Cathie Wood-run Ark Invest made some portfolio moves, notable among which is the offloading of a huge chunk of Stratasys Ltd. (NASDAQ: SSYS)...
Via
Benzinga
EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform
↗
June 30, 2022
Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
↗
June 21, 2022
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...
Via
Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
↗
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
June 22, 2022
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...
Via
FinancialNewsMedia
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
↗
June 21, 2022
Via
Benzinga
5 Cathie Wood Stocks to Buy in June
↗
June 09, 2022
These are the five best Cathie Wood stocks to buy in June. EXAS, IONS, KTOS, TRMB, and PATH can make excellent investments.
Via
InvestorPlace
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
↗
June 02, 2022
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Via
InvestorPlace
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
↗
May 20, 2022
Benzinga Pro data, Ionis Pharmaceuticals (NASDAQ:IONS) reported Q1 sales of $142.00 million. Earnings fell to a loss of $65.17 million, resulting in a 129.01% decrease from last quarter.
Via
Benzinga
What 5 Analyst Ratings Have To Say About Ionis Pharmaceuticals
↗
May 09, 2022
Within the last quarter, Ionis Pharmaceuticals (NASDAQ:IONS) has observed the following analyst ratings:
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
↗
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
How To Attend Ionis Pharmaceuticals Q1 2022 Earnings Conference Call
↗
April 25, 2022
Ionis Pharmaceuticals (NASDAQ:IONS) will host a conference call at 11:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
↗
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Ionis Pharma - AstraZeneca Antisense Medicine Met Its Primary, Secondary Goals To Lower Cholesterol
↗
April 04, 2022
Ionis Pharmaceuticals Inc (NASDAQ: IONS) and its partner, AstraZeneca Plc (NASDAQ: AZN), have
Via
Benzinga
Amylyx Pharmaceuticals Stock Crashes As FDA Doubts Its ALS Treatment
↗
March 28, 2022
Amylyx Pharmaceuticals could face an uphill battle for its ALS treatment this week.
Via
Investor's Business Daily
Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints
↗
March 28, 2022
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have
Via
Benzinga
Why Cramer Likes Ferguson And Stanley Black & Decker
↗
March 25, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) is a "momentum-driven stock" whose momentum he...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For March 11, 2022: Tesla, DTE Energy, Amazon And More
↗
March 11, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For March 2, 2022: VanEck Russia ETF, AMC Entertainment, SoFi Technologies And More
↗
March 02, 2022
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news...
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
